| Trial ID: | L7317 |
| Source ID: | NCT00823953
|
| Associated Drug: |
Momordica Charantia
|
| Title: |
Glycemic Response to Momordica Charantia in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Momordica charantia|OTHER: starch powder
|
| Outcome Measures: |
Primary: serum fructosamine at end of trial phase in each of the groups, three weeks | Secondary: Development of major adverse effects (e.g. intractable vomiting, jaundice, allergic reactions or other effects requiring cessation of therapy and breaking of study code), three weeks|GLP-1[7-36] in each group at the end of trial phase, three weeks|FBG at end of trial phase in each of the groups, three weeks|HOMA-IR in each of the two groups at end of trial phase, three weeks|Insulin resistance by the hyperinsulinemic, euglycemic clamp in a subset at the end of trial phase, 3 weeks
|
| Sponsor/Collaborators: |
Sponsor: Services Hospital, Lahore | Collaborators: University of the Punjab
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-11
|
| Completion Date: |
2009-02
|
| Results First Posted: |
|
| Last Update Posted: |
2012-06-12
|
| Locations: |
Services Hospital, Lahore, Punjab, 54000, Pakistan
|
| URL: |
https://clinicaltrials.gov/show/NCT00823953
|
